Protein transduction: A novel tool for tissue regeneration by Cardoso, M. C. & Leonhardt, H.
a rather low proliferative potential and are therefore diffi-
cult to obtain in meaningful quantities. In parallel, studies
on embryonic stem cells, which are by definition pluripo-
tent, are raising hopes of finding the ‘right way’ to direct
their differentiation into particular cell lineages. This ap-
proach is presently the subject of an intensive ethical de-
bate. 
Ways to Regenerate a Tissue
In principle, one could think of two ways to regenerate a
tissue:
(i) induce ‘neighboring’ cells to proliferate and/or trans-
differentiate;
(ii) transplant in vitro cultivated cells that can be differen-
tiated into the particular lineage.
In nature, one can find examples of both strategies to re-
place body parts (see Pearson, 2001). Within some inver-
tebrates such as the cnidarian Hydra, populations of
‘totipotent’ stem cells are present throughout their lives.
Upon transection, stem cells near the place of injury are
mobilized and respond to local cues, regrowing the miss-
ing body part. In some vertebrates, such as amphibian
urodeles, differentiated cells near the amputated plane
can start proliferating and become dedifferentiated.
These so-called blastemal cells produce a growing cone
of cells that progressively redifferentiate into the original
or other cell types needed to reconstruct the missing
body part (reviewed in Brockes, 1997). This cellular plas-
ticity is now the focus of intensive research aimed at
identifying the similarities and differences allowing regen-
eration in these organisms and failing in humans. Recent
studies mixing mouse and urodele skeletal muscle re-
vealed that the mouse cells could be stimulated to reen-
ter the cell cycle (McGann et al., 2001; Velloso et al.,
2001). Efforts are now concentrating on identifying the
factors that mediate the activation of proliferation in
mammalian skeletal muscle. 
Gene-Based Retrodifferentiation Approach
Earlier studies have shown that the proliferation arrest of
terminally differentiated mammalian cells is an actively
maintained state that can, in principle, be reversed. Our
knowledge of the molecular basis of cell cycle control
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Tissue regeneration in humans is limited and ex-
cludes vitals organs like heart and brain. Transforma-
tion experiments with oncogenes like T antigen have
shown that retrodifferentiation of the respective cells
is possible but hard to control. To bypass the risk of
cancer formation a protein therapy approach has
been developed. The transient delivery of proteins
rather than genes could still induce terminally-differ-
entiated cells to reenter the cell cycle. This approach
takes advantage of protein-transducing domains that
mediate the transfer of cargo proteins into cells. The
goal of this brief review is to outline the basics of pro-
tein transduction and to discuss potential applica-
tions for tissue regeneration.
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Introduction: The Price of Differentiation
Cellular differentiation, in general, is accompanied by
withdrawal from the cell cycle (Figure 1). That generates
on the one hand functional cells and tissues, which on the
other hand are mostly not capable of regeneration. In
terms of their respective proliferation potential, one can
grossly distinguish three types of cells in mammals: the
ones that are constantly dividing such as hematopoietic
stem cells and epithelial cells; the ones that are mostly
quiescent but can be stimulated to divide, including fi-
broblasts, hepatocytes, T and B cells; and the ones that
do not divide, including neurons, heart and skeletal mus-
cle cells. Particularly in the latter type, tissue repair after
injury or disease is a major unsolved problem.
In recent years, progress at many fronts has indicated
the existence of stem cells in adults that under some con-
ditions can be persuaded to transdifferentiate into differ-
ent cell lineages, unraveling a far greater plasticity than
previously expected (Figure 1). However, these cells have
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during terminal differentiation is still limited, but several of
the essential components and links have been identified
using the skeletal muscle system (reviewed by Cardoso
and Leonhardt, 1999). In mitogen-rich conditions, high
levels of the cell cycle activator, cyclin D1, mediate re-
pression of (i) retinoblastoma protein (pRb) growth
suppressive activity and (ii) MyoD transactivation of the
general cyclin-dependent kinase inhibitor p21cip1 and
muscle-specific genes, thus keeping myoblasts in a pro-
liferative state. Mitogen depletion (or other inductive
cues) induces the down-regulation of cyclin D1. This al-
lows accumulation of under-phosphorylated pRb, which
represses the transcription of proliferation-associated
genes by binding to E2F-DP transcription factor complex.
In addition, release of cyclin D1 inhibition of MyoD trans-
activation leads to the induction of the muscle differentia-
tion program and p21cip1 accumulation accompanied by
cell cycle withdrawal. 
Regulated expression of oncogenes such as SV40
large T antigen, which inhibits the pRb family of proteins,
stimulates cell cycle reentry (Endo and Nadal-Ginard,
1989; Cardoso et al., 1993). Other viral oncogenes have
also been shown, with different degrees of efficacy, to
stimulate proliferation of differentiated cells.
Another approach has been the generation of trans-
genic mice harboring a temperature-sensitive SV40 large
T antigen. Upon ex vivo cultivation at the permissive tem-
perature, these cells proliferated and could be expanded
in a manner dependent on active T antigen and, at least
in some cases, could be re-implanted de novo into mice
and redifferentiated (reviewed in Obinata, 1997).
In a related approach, reversible immortalization and
expansion of differentiated cells was achieved by viral
delivery of an excisable SV40 large T antigen, which was
later removed by bacteriophage Cre recombinase-medi-
ated excision. Importantly, after excision, the cells revert-
ed back to the differentiated phenotype (Li et al., 1997;
Berghella et al., 1999; Kobayashi et al., 2000).
All these studies have in common that they are based
on the delivery of the viral oncogene. Besides the hurdles
of gene delivery itself, none of these genetic methods
provides a good control over dose and time/duration of
delivery. Most importantly, a single ‘misguided’ DNA mol-
ecule inserted in an actively transcribed region of the host
chromosome could irreversibly transform the host and
thus give rise to a deadly tumor raising serious safety
concerns that at this moment seem to rule out any thera-
peutic applications.
Protein Transduction: An Alternative to
Genetic Manipulation
Until now the applicability of gene delivery systems such
as adenoviral vectors has been limited by problems to
sustain a stable transgene expression over long enough
time periods and by side effects like immunogenicity of
viral vectors or potential malignant transformation of tar-
get cells (reviewed by Verma and Somia, 1997). Further-
more, the efficacy of infection and transfection methods
is quite low in many differentiated cells.
The direct transfer of therapeutic proteins to target
cells would avoid irreversible genetic modification (mu-
tation) of targeted cells and would allow a better control
over dose and treatment duration. Protein therapy would
therefore be a very interesting alternative for a transient
and non-transforming effect since proteins get naturally
degraded and leave no traces behind. The fact that the
plasma membrane is rather impermeable (cut-off around
600 Da) has made intracellular delivery of large mole-
cules to cells without membrane disruption an impossi-
ble goal. In the last decade, the observation that some
viral and cellular proteins could transverse the cellular
membrane and be targeted to the cytoplasm and nucle-
us opened up totally new avenues to exploit protein
transduction for intracellular therapies and functional
studies in general.
The first case of a protein that could cross the lipid bi-
layer was the HIV-1 TAT protein (Frankel and Pabo, 1988;
Green and Loewenstein, 1988). A little later, a Drosophila
homeodomain transcription factor, Antennapedia, was
shown to also translocate across cellular membranes
(Joliot et al., 1991). Subsequent mapping identified short
peptide sequences in these proteins, rich in basic amino
acids that confer cellular internalization. The sequences
have therefore been named protein transducting do-
mains.
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Fig. 1 Progressive Loss of Proliferative Capacity during Differ-
entiation.
During the pre-implantation development cleavage cycles, from
the totipotent zygote to the blastocyst stage, high levels of pro-
liferation are maintained. Upon implantation and after birth, con-
comitant with the development of the different somatic lineages
and increased differentiation, a slow but progressive loss of pro-
liferation takes place. Several differentiated tissues such as
heart muscle, skeletal muscle and neurons become post-mitot-
ic, although in some cases limited populations of stem cells have
been found. Recent studies have shown that some of these
(stem) cells are able to differentiate into other cell lineages
(transdifferentiation). In addition, expression of e.g. oncogenes,
has been shown to be able to reverse the terminally differentiat-
ed state in some of these cells (retrodifferentiation).
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 13:42
Protein Transducing Domains (PTD)
PTD are peptide sequences from viral or cellular proteins
that can transduce across the plasma membrane in a re-
ceptor-independent manner. The most well-studied and
commonly used ones are: (i) HIV-1 TAT; (ii) HSV-1 VP22;
(iii) Drosophila Antennapedia. In addition, other proteins
have been reported to translocate across the membrane
in this unconventional manner. The latter proteins will not
be further mentioned here but several examples can be
found in Prochiantz (2000) and Futaki et al. (2001).
In general, the PTD vector peptide is covalently bound
to the cargo. Internalization has been in all cases shown
to occur at 37°C and at 4°C, and to be receptor inde-
pendent. To date, all cell types have been shown to be
transducible in vitro and in vivo. Upon import the com-
plex, in principle, does not dissociate, neither does it en-
ter the endocytic pathway. Transduction occurs in a con-
centration-dependent manner and within a few minutes,
allowing intracellular delivery of biomolecules in a time-
and dose-controlled manner.
The precise mechanism of PTD-mediated transloca-
tion through the membrane is not known but several
studies have investigated the minimal transduction do-
mains and potential structural requirements. To date, no
clear structural requirements have been identified.
Extensive mutagenesis studies have identified the es-
sential residues required for translocation in the 16 amino
acid-long Antennapedia peptide. In addition, a multitude
of cargoes have been cross-linked and delivered intracel-
lularly by this PTD. A shortcoming of this PTD is its inabil-
ity to internalize cargoes of sizes around or above 30 kDa,
as well as its relatively lower efficiency when compared
with the TAT PTD. Work on Antennapedia PTD has been
the subject of several excellent reviews (Prochiantz,
1996, 2000) and will not be further reviewed here.
HIV-1 TAT
TAT is a 101 amino acid immediate-early HIV protein that is
a powerful transactivator of gene expression and essential
for viral replication (reviewed in Jeang et al., 1999). As men-
tioned above, it was the first protein reported to be able to
translocate through the plasma membrane and enter the
nucleus (Frankel and Pabo, 1988; Green and Loewenstein,
1988). Its translocation ability was shown to be mediated
by an 11 amino acid-basic peptide [YGRKKRRQRRR]
(Vives et al., 1997). Subsequently, an ever-increasing num-
ber of fusion proteins and other cargoes ranging from small
molecules, peptides, anti-sense oligonucleotides to 200
nm-large liposomes, have been successfully transduced
via this PTD and other arginine- or lysine-rich peptides (re-
viewed in Wadia and Dowdy, 2002). Until now no size limit
has been established for this PTD.
The small size of this peptide and its high content of
arginines and lysines have prompted in the last years a
search for naturally or artificially improved PTDs. A col-
lection of the best PTDs from studies where the efficien-
cy of different PTDs was compared is summarized in
Table 1. As can be seen in the Table, a direct comparison
between reports is difficult since the individual studies
were done using different cells (a few also on animals)
and in some cases labeled peptides were tested on ‘in-
line’ fusion proteins or proteins conjugated to the pep-
tides in different ways. Nevertheless, in many cases ho-
mopolymers of arginine or lysine longer than 7 residues
transduce more efficiently than the TAT peptide itself.
The proposal that the guanidinium group of the argi-
nine residues is required for transduction (Wender et al.,
2000) does not seem to be an absolute requirement since
polylysine PTDs have been shown to transduce even
more efficiently than TAT or polyarginine PTDs (Mai et al.,
2002).
Many TAT fusion proteins have been shown to date to
enter the cell and retain functionality. In fact, it has even
been proposed that unfolded denatured proteins are bet-
ter transported across the lipid bilayer than native ones
and can regain their active conformation inside the cell
(Nagahara et al., 1998). Although the unfolded state
might help internalization, it is also not an absolute re-
quirement since other studies have successfully internal-
ized native proteins (Mi et al., 2000). Thus, protein trans-
duction technology has shown quite a degree of flexibility
making it somehow difficult to select a priori which strat-
egy or PTD is going to work best in a particular case.
One potential pitfall of these PTDs that has not re-
ceived enough attention is the tendency of these pep-
tides to accumulate in the nucleolus (Vives et al., 1997;
Futaki et al., 2001). This in principle unwanted feature is,
at least in some cases, dominant over other localization
sequences and can prevent the correct functioning of the
fused peptides or proteins (our unpublished results). A
possible way to circumvent this problem is to engineer in
vivo ‘cleavable’ peptides, which upon import into the in-
tercellular milieu will then separate from the vector pep-
tide. This approach has been successfully reported with
the Antennapedia peptide. The authors have linked the
Antennapedia peptide via a disulfide bond to the cargo.
This bridge is not stable in the cytoplasm due to the pres-
ence of high levels of glutathione and becomes reduced
in about an hour, liberating the cargo from the vector pep-
tide (Theodore et al., 1995; Prochiantz, 1996). This re-
moval of the PTD also prevents later extrusion of the car-
go out of the cell. Definitely, further work needs to be
done in order to target macromolecules to the desired
subcellular compartments of their action and to prevent
mistargeting of the cargo caused by the attached PTDs.
Recently, a novel protein delivery system was de-
scribed that is based on the HSV-1 protein VP22, which is
exported from cells by a Golgi-independent mechanism
and then spreads to neighboring cells (Elliott and O’Hare,
1997).
VP22
The 38 kDa viral phosphoprotein VP22 is a structural
component of HSV-1 located between capsid and tegu-
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ment. Its function in the viral life cycle is not clear. The C-
terminal half of the protein shares extensive homology
with tegument VP22 proteins from other herpes viruses
(Normand et al., 2001; Ren et al., 2001). This protein do-
main can be overproduced in bacteria and has been
shown in the presence of oligonucleotides to produce
spherical particles (named vectosomes) that can trans-
port these oligonucleotides into mammalian cells. Fur-
thermore, light activation can induce the release of the
cargo within seconds (Normand et al., 2001). 
VP22 has a complex pattern of localization in express-
ing cells. It is first detected in the cytoplasm where it can
bind and reorganize microtubules. When cells enter mito-
sis, it binds to chromatin and after cell division remains in
the nucleus of the daughter cells (Elliott and O’Hare, 2000).
Very little is known about intercellular transport or the ex-
port and import mechanisms involved in the VP22 intercel-
lular spreading process. Recent studies have mapped the
protein domains required for the different subcellular local-
izations as well as for intercellular spreading (Aints et al.,
2001; Ren et al., 2001; Martin et al., 2002).
As summarized in Table 2, different fusion proteins
have been generated and shown to spread and retain
their physiological effects. Most reports have concentrat-
ed on anti-tumor therapies either by induction of apopto-
sis upon delivery of functional p53 fused to VP22 (Phelan
et al., 1998; Wills et al., 2001; Zender et al., 2002) or by
delivering enzymes (thymidine kinase or cytosine deami-
nase) that allow the conversion of commonly used pro-
drugs into toxic compounds thereby inducing cell death
(Dilber et al., 1999; Liu et al., 2001; Wybranietz et al.,
2001). In some cases, coculture of VP22-producing
transfected cells and recipient cells was used. Other
studies tested whether the efficiency of viral delivery
would be enhanced by the subsequent ability of the pro-
duced proteins to spread into non-infected cells via the
VP22 moiety.
Due to the intended application in tumor therapy, most
studies to date have investigated the ability of VP22 to
spread between proliferating cells. We have further es-
tablished the ability of VP22 fusion proteins to spread into
terminally differentiated cells (Derer et al., 1999, 2002),
which is the prerequisite for any potential application in
tissue regeneration.
Direct Protein Delivery as a Tool for
Tissue Regeneration
A desirable regenerating agent should be able to induce
otherwise terminally differentiated cells to proliferate for
some time and disappear afterward leaving no traces be-
hind and permitting subsequent cellular redifferentiation.
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Table 1 ’Top’ Natural and Artificial PTDs.
PTD Uptake as Tested in Reference
RRQRRTSKLMKR peptide, fusion protein and conjugatea cell culture and animals Mi et al. (2000)
RRRRRRRRR labeled peptideb cell culture Wender et al. (2000)
YARAAARQARA labeled peptide cell culture and animals Ho et al. (2001)
RRRRRRRR peptide and cross-linked protein cell culture Futaki et al. (2001)
RRRRRRRRR fusion protein cell culture Han et al. (2001)
KKKKKKKK protein conjugatec cell cultured Mai et al. (2002)
KKKKKKKKK fusion protein cell culture and animals Park et al. (2002)
Collection of the most efficient PTDs from comparative studies where the uptake of different peptides was tested.
aBiotinylated peptide conjugated to avidin-linked β-galactosidase or fluorochrome.
bD-isomers were more efficient than L-isomers.
cBiotinylated peptide conjugated to streptavidin-linked β-galactosidase.
dUptake efficiency highly dependent on the cell line and enhanced by dextran sulfate.
Table 2 Summary of Proteins Transduced via Fusion to VP22.
Protein fused to VP22 Physiological effect Tested in Reference
p53 induction of apoptosis cell culturea Phelan et al. (1998)
HSV thymidine kinase suicide cell death cell culture and animalsa,b Dilber et al. (1999)
HSV thymidine kinase suicide cell death cell culturea Liu et al. (2001)
p53 induction of apoptosis cell culture and animalsb Wills et al. (2001)
cytosine deaminase suicide cell death cell cultureb Wybranietz et al. (2001)
SV40 T antigen cell cycle reinduction cell culturea Derer et al. (2002)
p53 induction of apoptosis cell culture and animalsa,b Zender et al. (2002)
Proteins such as β-galactosidase or GFP are not included since they are only used as reporters to test efficiency.
aCoculture of VP22-producing cells with recipient cells.
bVP22 fusion encoded in viral vectors.
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Since in most cases of unscheduled proliferation cells
activate their apoptosis program, the ideal agent should
also be able to prevent the programmed cell death. It
would in addition be desirable to have an agent that acts
topically so as to allow regeneration of the specific tissue
and not at other body parts. For that purpose, either a
very rapid uptake of the regenerating agent, or ex vivo ap-
plication, followed by grafting of the expanded and differ-
entiated cells, would be two possible alternatives. Most
factors that can induce differentiated cells to reenter the
cell cycle are powerful oncogenes, i.e., they can induce
tumors. This capacity of oncogenes to permanently
transform cells that could then give rise to tumors consti-
tutes a serious risk and argues against gene-based ap-
proaches. Therefore, a transient and non-transforming
approach such as protein transduction, i.e., direct deliv-
ery of the oncogene product rather than the gene itself,
seems to be the method of choice.
The proof-of-concept that protein transduction can be
used to induce proliferation in terminally differentiated
cells was recently obtained (Derer et al., 2002). In this
study, cells overproducing a fusion of VP22 with SV40
large T antigen were cocultured with differentiated skele-
tal muscle cells. VP22 was shown to mediate the traffick-
ing of SV40 large T antigen into the differentiated my-
otubes where it accumulated in the nucleus. The fusion
protein was also able to activate cell cycle reentry in
these differentiated cells. 
SV 40 large T antigen combines the ability to release
the cell cycle block maintained by the retinoblastoma
family of tumor suppressors, to block apoptosis (re-
viewed in Ali and DeCaprio, 2001) and possibly even to
activate telomerase, preventing telomere shortening
(Foddis et al., 2002). Furthermore, gene-based ap-
proaches have indicated that upon removal of T antigen,
cells revert back to the differentiated phenotype (Li et al.,
1997; Obinata, 1997; Berghella et al., 1999; Kobayashi
et al., 2000). Therefore, this oncoprotein is an ideal candi-
date for a regenerating agent.
Another advantage of the direct delivery approach is
the fact that it allows for easy combinatorial therapies us-
ing a mixture of different factors, which would be rather
difficult to achieve with gene-based methods. A potential
pitfall of longer term applications is the likely develop-
ment of an immune reaction to the administered agent.
Methods of circumventing this problem are already in
use, and involve, in addition to immune suppression,
generation of functional mutants of the delivered protein
or homologs from other species (reviewed in Ford et al.,
2001).
Certainly, several steps need to be optimized before
the therapeutical application of this protein transduction
approach for tissue regeneration. Based on our recent re-
sults using a T antigen fusion protein (Derer et al., 2002)
we propose the approach for tissue regeneration outlined
in Figure 2 that could in principle be used directly on
damaged tissues or indirectly by expanding cells ex vivo
for later engrafting. Purified PTD-T antigen is added to
the cell culture medium in ex vivo cultures or applied to
the damaged tissue, where it crosses the plasma mem-
brane and enters the nucleus. There SV40 large T antigen
binds pRb and p53, among other cellular proteins, and
induces cellular proliferation. Upon attaining sufficient
cell numbers, addition of PTD-T antigen is stopped. Over
time the remaining fusion protein gets naturally degraded
allowing the cells to redifferentiate and to functionally re-
place the damaged tissue.
In the near future, the purification of PTD-T antigen fu-
sion proteins, as well as other potential candidates and
mixtures thereof, is necessary to evaluate and optimize
their potential to elicit transient expansion of differentiat-
ed cells in vitro and in vivo. In parallel, the feasibility of us-
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Fig. 2 Protein Transduction as a Tool to Transiently Induce Retrodifferentiation.
The outlined strategy is based on some recent results obtained with an SV40 T antigen fusion (Derer et al., 2002). Chimeric proteins
composed of PTD and SV40 T antigen (PTD-T antigen) transverse the cell membrane and enter the nucleus of terminally differentiated
cells. The multifunctional viral T antigen protein releases the cell cycle arrest actively maintained by the retinoblastoma family of pro-
teins and prevents apoptosis mediated by p53, thereby allowing expression of cell cycle activators and induction of cellular prolifera-
tion. Once the supply of fresh PTD-T antigen is discontinued, the remaining fusion protein gets naturally degraded and leaves no traces
behind, allowing subsequent redifferentiation of the cells.
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ing PTDs that get cleaved off within the cell should be
tested for this approach. Furthermore, fast and efficient
transduction might allow topical administration of the
chosen regeneration agent. Finally, estimating and engi-
neering the half-life of the regeneration factor in different
cellular and extracellular environments will be necessary.
Although a lot of work still lies ahead, the potential of this
strategy amply justifies the effort.
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